Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 9, 2002, Pages 497-502

  Kasper, C ^a   Zahner, J ^b   Sayer, H G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Medical Department   (Germany)

Author keywords

Anemia; Erythropoietin; Granulocyte colony stimulating factor (G CSF); Granulocyte macrophage colony stimulating factor (GM CSF); Myelodysplastic syndrome (MDS)

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; MYELODYSPLASTIC SYNDROMES;

EID: 0036379230     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0372-z     Document Type: Article

References (36)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
2. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R (1996) A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anemia in myelodysplastic syndromes. Leukemia Res 20:693-699
3. Bunn HF (2002). Drug-induced autoimmune red-cell aplasia. N Engl J Med 346:522-523
4. Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SNJ, Bracos M, Stewart CC, Baer MR (2001) Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98:3492-3494
5. Casadevall N, Lepage E, Durieux O, Dubois S, Dreyfus F, Quarre MC, Fenaux P, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Vekhoff A, Ribrag V (2001) Erythropoietin (RHuEPO) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results from a randomized trial with impact on quality of life and costs. Hematol J 1(S1):687
6. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475
7. Donahue RE, Emerson SG, Wang EA, Wong GG, Clark SC, Nathan GD (1985). Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin. Blood 66:1479-1481
8. Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S (1999) Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony stimulating factor plus recombinant human erythropoietin. Leukemia 13:1009-1012
9. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennet J (1997) International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
10. Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, Sanpaolo G (2002) Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica 87:322-323
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink K, Vardiman J, Lister TA, Bloomfield C (1999) World Health Organization classification of neoplastic diseases of the he-matopoietic and lymphoid tissue: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
12. Hansen PB, Johnsen HE, Hippe E, Hellström-Lindberg E, Ralfkiaer E (1993) Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol 44:229-236
13. Hellström-Lindberg E (1994) Efficiency of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71
14. Hellström-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen J-M, Winqvist I, Öst A (1993) A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221-228
15. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Öst Å, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patinets with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344-351
16. Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen J-M, Winqvist I, Öberg G, Österborg A, Öst A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75
17. Hogge DE, Cashman JD, Humphries RK, Eaves CJ (1991). Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures. Blood 77:493-499
18. Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y, Yachi A, Kudoh T, Chiba S, Kasai M, Oka T, Okuno A, Maekawa I, Sakurada K, Miyazaki T (1993) Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 68:163-166
19. Italian cooperative study group for rHuEPO in myelodysplastic syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070-1074
20. Koury MJ, Bondurant MC (1992). The molecular mechanism of erythropoietin action. Eur J Biochem 210:649-663
21. Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, Tesch H (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Bri J Haematol 109:367-375
22. Mayani H, Baines P, Bowen DT, Jacobs A (1989). In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia 3:29-32
23. Miller AM, Noyes WE, Taetle R, List AF (1999) Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. Leuk Res 23:77-83
24. Musto P, Sanpaolo G, D'Arena G, Scalzulli PS, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M (2001) Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44-51
25. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076-4081
26. Nösslinger T, Reisner R, Koller E, Grüner H, Tückler H, Nowotny H, Pittermann E, Pfeilstöcker M (2001). Myelodysplastic syndromes, from French-American-British to Eorl Health Organization: comparison of classification on 431 unselected patients from a single institution. Blood 98:2935-2941
27. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965
28. Remacha AF, Arrizablaga B, Villegas A, Manteiga R, Calvo T, Julià A, Fuertes MIF, Gonzáles FA, Font L, Juncà J, Del Arco A, Malcorra JJ, Equiza EP, De Mendiguren BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 84:1058-1064
29. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W (1995) Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 54:39-45
30. Sawada K, Krantz SB, Dai CH, Koury ST, Horn ST, Glick AD, Civin CI (1990). Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 142:219-230
31. Skibel V, Nissen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98:3626-3634
32. Stasi R, Pagano A, Terzoli E, Amadori S (1999) Recombinant human granulocyte-macrophage colony stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 105:141-148
33. Stasi R, Brunetti M, Terzoli E, Amadori S (2002) Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99:1578-1584
34. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH, GM/EPO MDS study group (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179
35. Verhoef GEG, Boogaerts MA (1996) rhEPO in the treatment of the myelodysplastic syndromes. In: Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rh Erythropoietin in cancer supportive treatment. Marcel Dekker, New York, p 13-34
36. Verhoef GEG, Demuynck H, Zachée P, Ceuppens J, De Witte M, Boogaerts MA (1993) Treatment of myelodysplastic syndromes with the combination f interleukin-3 and erythropoietin. Blood 82(S1):377a